[Efficacy of infliximab in treatment of pediatric XXXX in China].

@entity1 @entity33 @entity699 @entity2837 @entity230 @entity30 @entity2983 @entity288
OBJECTIVE: To investigate the efficacy of infliximab versus corticosteroids in achieving clinical remission in pediatric @entity1 with @entity30 in China. METHOD: Data of all newly diagnosed active @entity30 pediatric cases seen from June 2009 to December 2013 in @entity1 's Hospital, Zhejiang University School of @entity2837 were retrospectively recorded and reviewed. INCLUSION CRITERIA: the age of the @entity1 was less than 18 years; pediatric @entity30 activity index (PCDAI) was more than 10; infliximab or corticosteroids were used for inducing remission; infliximab, immunosuppressive medications or @entity2983 was prescribed for maintaining remission. @entity1 in @entity230 group were followed up for more than 1 year. The enrolled @entity1 were divided into two groups: infliximab group and @entity230 group. Clinical data, laboratory findings and side effects of the medications were collected at week 2, 4, 12, 24 and 48. PCDAI and @entity30 endoscopic index score (CDEIS) were calculated. Clinical response rate, clinical remission rate, relapse rate, @entity33 and growth were evaluated. RESULT: Eleven @entity1 received infliximab therapy and 11 subjects received corticosteroids. In Infliximab group, 6, 5 and 7 @entity1 were in clinical remission at week 2, 4, and 8, while so were 6, 9, and 9 @entity1 in @entity230 group. The difference was not statistically significant (     = 0.00, 3.14, 0.92, P > 0.05). In infliximab group, 8, 8, and 11 @entity1 were in clinical remission at week 2, 4, and 8, so were 8, 9, and 9 @entity1 in @entity230 group. The difference was not statistically significant (     = 0.00,0.26, 2.20, P > 0.05). When compared with data at baseline, significant decreases were observed in the median PCDAI between the two groups at week 2, 4, and 8 (all P < 0.05). But there were no significant differences between two groups at week 2, 4, and 8 (all P > 0.05). At week 12, 24 and 48, 8/11, 7/8, 3/5 cases on infliximab versus 7/11, 9/11, 8/11 cases on @entity230 maintained remission. There was no significant differences between the two groups (all P > 0.05). In 7 @entity1 and 9 @entity1 remission was successfully induced at week 8. The relapse rate was similar at week 12, 24, and 48 (     = 0.83, 0.09, 1.00, all P > 0.05). Height for age Z score in infliximab group was significantly higher than that in @entity230 group at week 24 (P < 0.05). Body mass index Z score between the two groups at week 8, 24, and 48 were not statistically significant (all P > 0.05). Of the @entity1 treated with infliximab, 3 developed side effects. All the @entity1 treated with @entity230 got @entity699 . CONCLUSION: In @entity1 with @entity30 , infliximab therapy is as effective as @entity288 to induce remission.Less side effects were observed with infliximab therapy compared with immunosuppressive medication and @entity2983 .
